Protein kinase C in the treatment of disease: Signal transduction pathways, inhibitors, and agents in development

Current Medicinal Chemistry

Volumn 6, Issue 9, 1999, Pages 877-903

  Goekjian, Peter G ^a   Jirousek, Michael R ^b  

^a MISSISSIPPI STATE UNIVERSITY   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 3 [8 [(DIMETHYLAMINO)METHYL] 6,7,8,9 TETRAHYDROPYRIDO[1,2 A]INDOL 10 YL] 4 (1 METHYL 1H INDOL 3 YL) 1H PYRROLE 2,5 DIONE; BALANOL; BRYOSTATIN 1; CPR 1006; GO 7611; ISIS 3521; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN; SPC 100840; UNCLASSIFIED DRUG;

ARTICLE; CANCER; CARDIOVASCULAR DISEASE; DRUG POTENCY; ENZYME ACTIVITY; HUMAN; IMMUNOPATHOLOGY; INFECTION; PERIPHERAL VASCULAR DISEASE; SIGNAL TRANSDUCTION;

AZEPINES; CARBAZOLES; ENZYME INHIBITORS; HUMANS; HYDROXYBENZOIC ACIDS; INDOLES; LACTONES; MACROLIDES; MALEIMIDES; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PROTEIN KINASE C; PYRROLES; SIGNAL TRANSDUCTION; THIONUCLEOTIDES;

EID: 0032847677     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (190)

1. The role of protein kinase C in cell surface signal transduction and tumor promotion. Nishizuka, Y. Nature 1984, 308(59-61), 693-8.
2. Protein Kinase C. Parker, P. J.; Dekker, L. V., Eds. Springer: London 1997.
3. Structural Basis of Protein Kinase C Activation by Tumor Promoters. Kishi, Y.; Rando, R. R. Acc Chem Res 1998, 31(4), 163-172.
4. The extended protein kinase C superfamily. Mellor, H.; Parker, P. J. Biochem J 1998, 332(2), 281-292.
5. Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. II. Proenzyme and its activation by calcium-dependent protease from rat brain. Inoue, M.; Kishimoto, A.; Takai, Y.; Nishizuka, Y. J Biol Chem 1977, 252(21), 7610-6.
6. Protein kinase C: a paradigm for regulation of protein function by two membrane-targeting modules. Newton, A. C.; Johnson, J. E. Biochim Biophys Acta 1998, 1376(2), 155-172.
7. Crystal structure of the cys2 activator-binding domain of protein kinase C delta in complex with phorbol ester. Zhang, G.; Kazanietz, M. G.; Blumberg, P. M.; Hurley, J. H. Cell 1995, 81(6), 917-24.
8. Anchoring proteins for protein kinase C: a means for isozyme selectivity. Mochly-Rosen, D.; Gordon, A. S. Faseb J 1998, 12(1), 35-42.
9. PKC downregulation: signal or adaptation? Pears, C. J.; Goode, N. T., p. 45-56 in reference 2, 1997.
10. Signaling through protein kinase C. Toker, A. Front Biosci 1998, 3, D1134-1147.
11. PKC and lipid signaling for sustained cellular responses. Nishizuka, J. Faseb J 1995, 9, 484-496.
12. Tyrosine phosphorylation of protein kinase C-delta in response to its activation. Li, W.; Mischak, H.; Yu, J. C.; Wang, L. M.; Mushinski, J. F.; Heidaran, M. A.; Pierce, J. H. J Biol Chem 1994, 269(4), 2349-52.
13. Regulation of atypical ζ-protein kinase C in cellular signaling. Zhou, G.; Wooten, M. W.; Coleman, E. S. Exp Cell Res 1994, 214, 1-11.
14. Signal transduction by protein kinase C in mammalian cells. Kanashiro, C. A.; Khalil, R. A. Clin Exp Pharmacol Physiol 1998, 25(12), 974-985.
15. The distinct biological potential of PKC isotypes. Ohno, S., p. 75-95 in reference 2 1997.
16. Modulating protein kinase C signal transduction. Mochly-Rosen, D.; Kauvar, L. M. Adv Pharmacol 1998, 44, 91-145.
17. Up-regulation of intracellular signaling pathways may play a central pathogenic role in hypertension, atherogenesis, insulin resistance, and cancer promotion - the 'PKC syndrome'. McCarty M. F. Med Hypotheses 1996, 46(3), 191-221.
18. Protein kinase C, a therapeutic target. Nambi, P.; Amegadzie, B.; Mattem, M. Pharmacol Rev Commun. 1996, 8(1), 29-38.
19. Targeting signal transduction for disease therapy. Levitzki, A. Med Oncol 1997, 14(2), 83-9.
20. Therapeutic potential of protein kinase C inhibitors. Bradshaw, D.; Hill, C. H.; Nixon, J. S.; Wilkinson, S. E. Agents & Actions 1993, 38(1-2), 135-47.
21. The Protein Kinase Facts Book, Hardie, G.; Hanks, S. , Eds.; Academic Press: San Diego 1995.
22. Protein kinase C: is its pivotal role in cellular activation overstated? Wilkinson, S. E.; Hallam, T. J. Trends Pharmacol Sci 1994, 15(2), 53-7.
23. The protein kinase C inhibitors Ro318220 and GF109203X are equally potent inhibitors of MAPKAP kinase-1β (Rsk-2) and p70S6 kinase. Alessi, D. R. FEBS Lett. 1997, 402(2,3), 121-123.
24. (S)-13-((Dimethylamino)Methyl)-10, 11, 14, 15-Tetrahydro-4,9/16,21-Dimetheno-1H, 13H-Dibenzo(E,K)Pyrrolo(3,4-H)(1,4,13)Oxadiazacyclohexadecene-1,3(2H)-Dione (Ly333531) and Related Analogs - Isozyme-Selective Inhibitors of Protein-Kinase C-Beta. Jirousek, M.; Gillig, J.; Gonzalez, C.; Heath, W. McDonald, J.; Neel, D.; Rito, C.; Singh, U.; Stramm, L. Melikianbadalian, A.; Baevsky, M.; Ballas, L.; Hall, S. Winneroski, L.; Faul, M. J Med Chem 1996, 39, 2664-2671.
25. (a) Antisense oligodesoxynucleotide strategies in renal and cardiovascular disease. Haller, H.; Maasch, C.; Dragun, D.; Wellner, M.; von Janta-Lipinski, M.; Luft, F. C. Kidney Int 1998, 53(6), 1550-8.
26. (b) Antisense oligonucleotide inhibitors of isozymes of protein kinase C: in vitro and in vivo activity, and clinical development as anti-cancer therapeutics. McGraw, K.; McKay, R.; Miraglia, L.; Boggs, R. T.; Pribble, J. P.; Muller, M.; Geiger, T.; Fabbro, D.; Dean, N. M. Anticancer Drug Des 1997, 12(5), 315-26.
27. Protein kinase C in normal and pathologic myocardial states. Cain, B. S.; Meldrum, D. R.; Harken, A. H. J Surg Res 1999, 81(2), 249-59.
28. Cardiac protein phosphorylation: functional and pathophysiological correlates. Rapundalo, S. T. Cardiovasc Res 1998, 35(3), 559-88.
29. PKC-dependent signaling mechanisms in differentiated smooth muscle. Morgan, K. G.; Leinweber, B. D. Acta Physiol Scand 1998, 164(4), 495-505.
30. Vascular biology of endothelin. Schiffrin, E. L.; Touyz, R. M. J Cardiovasc Pharmacol 1998, 32(Suppl. 3), S2-S13.
31. Molecular and cellular mechanisms of action of angiotensin II (AT1) receptors in vascular smooth muscle. Hughes, A. D. J Hum Hypertens 1998, 12(5), 275-81
32. Cellular and molecular biology of vascular smooth muscle cells in pulmonary hypertension. Voelkel, N. F.; Tuder, R. M. Pulm Pharmacol Ther 1997, 10(5/6), 231-241.
33. Opioid peptide gene expression in the myocardial cell. Ventura, C.; Pintus, G.; Tadolini, B. Trends Cardiovasc Med 1998, 8(3), 102-110.
34. Vascular dopamine-I receptors and atherosclerosis. Yasunari, K.; Kohno, M.; Kano, H.; Yokokawa, K.; Minami, M.; Yoshikawa, J. J Atheroscler Thromb 1997, 4(2), 59-64.
35. Polyunsaturated fatty acids and signaling via phospholipase C-β and A2 in myocardium, de Jonge, H. W.; Dekkers, D. H. W.; Lamers, J. M. J. Mol Cell Biochem 1996, 157(1&2), 199-210.
36. Active oxygen species as signaling mediators in the vascular system. Laurindo, F. R. M.; Pedro, M. De A.; Da Luz, P. L.; Augusto, O. Cienc Cult(Sao Paulo) 1996, 48(1/2), 18-27.
37. Modulation of the calcium sensitivity of the smooth muscle contractile apparatus: molecular mechanisms, pharmacological and pathophysiological implications. Savineau, J. P.; Marthan, R. Fundam Clin Pharmacol 1997, 11(4), 289-299.
38. Regulation of smooth muscle actin-myosin interaction and force by calponin. Winder, S. J.; Allen, B. G.; Clement-Chomienne, O.; Walsh, M. P. Acta Physiol Scand 1998, 164(4), 415-426.
39. Structure and expression of vascular smooth muscle calponin. Takahashi, K.; Masuda, H.; Takagi, M.; Eshita, Y.; Shibata, N. Regul Contract Cycle Smooth Muscle, 201-209. Editor(s): Nakano, T.; Hartshorne, D. J. Springer : Tokyo, Japan. 1995.
40. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. Ishii, H.; Koya, D.; King, G. L. J Mol Med (Berlin) 1998, 76(1), 21-31.
41. Signaling by protein kinase C isozymes in the heart. Puceat, M.; Vassort, G. Mol Cell Biochem 1996, 157(1&2), 65-72.
42. Atherogenesis and ischemic heart disease. Selwyn A. P.; Kinlay S.; Ganz P. Am J Cardiol 1997, 80(8B), 3H-7H.
43. Signal transduction in vascular smooth muscle. Alexander R.W.; Griendling K. K. J Hypertens 1996, Suppl. 74(5), S51-4.
44. Shear stress and platelet-derived microparticles. Rinsho Byori 1997, 45(10), 927-933.
45. Ox-LDL induces apoptosis in human coronary artery endothelial cells: role of PKC, PTK, bcl-2, and Fas. Li, D.; Yang B.; Mehta, J. L. Am J Physiol 1998, 275, H568-576.
46. Dopamine D1 receptor and protein kinase C isozymes in spontaneously hypertensive rats. Yao, L. P.; Li, X. X. ; Yu, P. Y.; Xu, J.; Asico, L. D.; Jose P. A. Hypertension 1998, 32(6), 1049-53.
47. Signaling pathways for cardiac hypertrophy. Yamazaki T.; Komuro I.; Yazaki Y. Cell Signal 1998, 70(10), 693-8.
48. Cellular mechanisms of cardiac hypertrophy. Sugden P.H.; Clerk A. J. Mol Med 1998 76(11), 725-46.
49. The role of protein kinases in adaptational growth of the heart. Bogoyevitch, M. A.; Sugden, P. H. Int J Biochem Cell Biol 1996, 28(1), 1-12.
50. (a) Regulation of the angiotensin receptor subtypes in cell cultures, animal models and human diseases. Regitz-Zagrosek, V.; Auch-Schwelk, W.; Neuss, M.; Fleck, E. Eur Heart J 1994, 15(Suppl. D), 92-7.
51. (b) Angiotensin receptors - organ- and subtype-specific regulation in cardiovascular disease and with modulation of the renin-angiotensin system. Studies in a rat model and in human myocardium. Regitz-Zagrosek, V.; Neuss, M.; Warnecke, C.; Holzmeister, J.; Hildebrand, A. G.; Fleck, E. Z Kardiol 1995, 84(Suppl. 4), 61-9.
52. Hypertensive cardiac hypertrophy. Haneda, T.; Osaki, J.; Kikuchi, K. Saishin Igaku 1996, Suppl. 609, 841-50.
53. Role of protein kinase C as a cellular mediator of ischemic preconditioning: a critical review. Simkhovich B. Z.; Przyklenk K.; Kloner R. A. Cardiovasc Res 1998, 40(1), 9-22.
54. Arguments in favor of protein kinase C playing an important role in ischemic preconditioning. Downey J. M., Cohen M. V. Basic Res Cardiol 1997, 92 Suppl. 2, 37-9.
55. (a) Myocardial, neural and vascular aspects of ischemic preconditioning. Losano, G.; Gattullo, D.; Pagliaro, P. Life Sci 1996, 59(15), 1185-1192.
56. (b) Myocardial preconditioning promises to be a novel approach to the treatment of ischemic heart disease. Cohen, M. V.; Downey, J. M. Annu Rev Med 1996, 47, 21-9.
57. (a) Protection of the myocardium by ischemic preconditioning: mechanisms and therapeutic implications. Millar, C. G. M.; Baster, G. F.; Thiemermann, C. Pharmacol Ther 1996, 69(2), 143-51.
58. (b) Myocardial preconditioning: cellular mechanisms and perspectives for pharmacological induction. Rapundalo, S. T.; Edmunds, J. J.; Gallagher, K. P. Curr Pharm Des 1995, 1(4), 483-506.
59. Role of PKC and tyrosine kinase in ethanol-mediated inhibition of LPS-inducible nitric oxide synthase. Greenberg S. S.; Jie O.; Zhao X.; Wang J. F. Alcohol 1998 16(2), 167-75.
60. Neurohormonal activation and nitrate tolerance: implications for concomitant therapy with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Munzel, T.; Heitzer, T.; Brockhoff, C. Am J Cardiol 1998, 81(1A), 30A-40A.
61. Nitric oxide availability in diabetes mellitus. Honing, M. L.; Morrison, P. J.; Banga, J. D.; Stroes, E. S.; Rabelink, T. J. Diabetes Metab Rev 1998, 14(3), 241-9.
62. The effects of various drugs on the myocardial inotropic response. Endoh, M. Gen Pharmacol 1995, 26(1), 1-31.
63. Current Therapy of Diabetes Mellitus. DeFronzo, R. A., Ed. Mosby-Year Books : St. Louis 1998.
64. The Diabetes Control and Complications Trial Research Group, N Engl J Med 1993, 329, 977-986.
65. Protein kinase C activation and the development of diabetic complications. Koya, D.; King, G. L. Diabetes 1998, 47(6), 859-66.
66. Color Atlas of Biochemistry. Koolman, J. Thieme Medical Publishers: New York 1996.
67. Structure-function relationships of cation binding in the Na(+)/K(+)-ATPase. Vasilets, L. A.; Schwarz, W. Biochim Biophys Acta 1993, 1154(2), 201-22.
68. Elevated Glucose Level regulates epidermal growth factor receptor (EGF-R) in aortic smooth muscle cells overexpressing protein kinase C. Xia, P.; Feener, E. P.; King, G. L. Diabetes 1994, 43(Suppl. 1), 101A.
69. Calphostin-C stimulates epidermal growth factor receptor phosphorylation and internalization via light-dependent mechanism. Gamou, S.; Shimizu, N. J Cell Physiol 1994, 158(1), 151-9.
70. Protein Kinase C as a Target for Cardiac Failure. Vlahos, C. J. Progress Towards Signal Transduction and Gene-Pegulating Drugs July 13, 1998, San Diego, CA.
71. Protein kinase C-zeta as a downstream effector of phosphatidylinositol 3-kinase during insulin stimulation in rat adipocytes. Potential role in glucose transport. Standaert, M. L.; Galloway, L.; Karnam, P.; Bandyopadhyay, G.; Moscat, J.; Farese, R. V. J Biol Chem 1997, 272(48), 30075-82.
72. Blackshear, P. J. The Role (or Lack Thereof) of Protein Kinase C in Insulin Action, Chapter 11 in Draznin, B.; LeRoith, D., Eds. Molecular Biology of Diabetes, Humana Press, Totowa NJ 1994.
73. Mechanisms of insulin resistance and new pharmacological approaches to metabolism and diabetic complications. Donnelly, R.; Qu, X. Clin Exp Pharmacol Physiol 1998, 25(2), 79-87.
74. Protein kinase C and tumorigenic potential. Baron-Delage S, Cherqui G Bull Cancer 1997 84(8), 829-32.
75. Protein kinase C: a worthwhile target for anticancer drugs? Caponigro F, French, R. C.; Kaye, S. B. Anticancer Drugs 1997, 8(1), 26-33.
76. Suppression of protein kinase C and nuclear oncogene expression as possible molecular mechanisms of cancer chemoprevention by apigenin and curcumin. Lin, J.-K.; Chen, Y.-C.; Huang, Y.-T.; Lin-Shiau, S.-Y. J Cell Biochem 1998, Issue Suppl. 28/29, 39-48.
77. The Emerging Role of Protein Phosphorylation and Cell Cycle Control in Tumor Progression. Bridges, A. J. Chemtracts 1995, 8, 73-107.
78. The role of protein kinase C in cellular proliferation and cell cycle control. Murray, N. R.; Thompson, L. J.; Fields, A. P., p 97 -120 in reference 2.
79. (a) Overcoming drug resistance in lung cancer. Saijo, N.; Nishio, K.; Yoshida, M. Oncology 1998, 12(1 Suppl 2), 87-9.
80. (b) Target to apoptosis: a hopeful weapon for prostate cancer. Tang, D. G.; Porter, A. T. Prostate 1997, 32(4), 284-93.
81. Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis. Deacon, E. M.; Pongracz, J.; Griffiths, G.; Lord, J. M. Mol Pathol 1997 50(3), 124-31.
82. Indolocarbazoles as anti-cancer agents. Prudhomme, M. Curr Pharm Des 1997, 3(3), 265-290.
83. Molecular basis of targeted chemotherapy: novel concepts with special reference to the treatment of Hodgkin's disease. Grunicke, H. H. Ann Oncol 1998;9, Suppl 5, S125-8.
84. Protein kinase C-alpha: a novel target for the therapy of androgen-independent prostate cancer? (Review-hypothesis). O'Brian, C. A. Oncol Rep 1998, 5(2), 305-9.
85. The role of protein kinase C (PKC) in the evolution and proliferation of malignant gliomas, and the application of PKC inhibition as a novel approach to anti-glioma therapy. Bredel, M.; Pollack, I. F. Acta Neurochir (Wien) 1997, 139(11), 1000-13.
86. Timing of dietary fat exposure and mammary tumorigenesis: role of estrogen receptor and protein kinase C activity. Hilakivi-Clarke, L.; Clarke, R. Mol Cell Biochem 1998, 188(1-2), 5-12.
87. The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogenesis. Yuspa, S. H.; J Dermatol Sci 1998, 17(1), 1-7.
88. Modulation of intracellular second messengers by dietary fat during colonic tumor development. Chapkin, R. S.; Jiang, Y. H.; Davidson, L. A.; Lupton, J. R.; Adv Exp Med Biol 1997, 422, 85-96.
89. Protein kinase C: a physiological mediator of enhanced transmitter output. Majewski, H.; Iannazzo, L. Prog Neurobiol 1998, 55(5), 463-75.
90. The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotropin receptor signaling. Rossner, S.; Ueberham, U.; Schliebs, R.; Perez-Polo, J. R.; Bigl, V. Prog Neurobiol 1998, 56(5), 541-569.
91. Regulation of APP metabolism by protein phosphorylation. Buxbaum, J. D.; Ikin, A.; Luo, Y.; Naslund, J.; Sabo, S.; Vincent, B.; Watanabe, T.; Greengard, P. Adv Behav Biol 1998, 49, 133-140.
92. Cholinergic muscarinic receptor signaling by the phosphoinositide signal transduction system in Alzheimer's disease. Jope, R. S. Alzheimer's Dis Rev 1996, 1(1/2), 2-14.
93. Regulation of presenilin 1 phosphorylation and transcriptional activation of signal transduction-induced genes by muscarinic receptors. Langer, U.; Albrecht, C.; Mayhaus, M.; Velden, J.; Wiegmann, H.; Klaudiny, J.; Muller, D.; Von Der Kammer, H.; Nitsch, R. M. Presenilins Alzheimer's Dis 1998, 79-84.
94. Specific role for protein kinase C alpha in the constitutive and regulated secretion of amyloid precursor protein in human skin fibroblasts. Benussi, L.; Qovoni, S.; Gasparini, L.; Binetti, G.; Trabucchi, M.; Bianchetti, A.; Racchi, M. Neurosci Lett 1998, 240(2), 97-101.
95. Soluble β-amyloid induces Alzheimer's disease features in human fibroblasts and in neuronal tissues. Etcheberrigaray, R.; Payne, J. L.; Alkon, D. L. Life Sci. 1996, 59(5/6), 491-498.
96. Effect of reduced myristoylated alanine-rich C kinase substrate expression on hippocampal mossy fiber development and spatial learning in mutant mice: transgenic rescue and interactions with gene background. McNamara, R. K.; Stumpo, D. J.; Morel, L. M.; Lewis, M. H.; Wakeland, E. K.; Blackshear, P. J.; Lenox, R. H.; Proc Natl Acad Sci U S A 1998, 95(24), 14517-22.
97. Behavioral, electrophysiological, and biochemical consequences of chronic cytochrome oxidase inhibition in rats. Bennett, M. C.; Rose, G. M. Cytochrome Oxidase Neuronal Metab Alzheimer's Dis, [Proc. Int.] 1998, 217-232.
98. Time domains of neuronal Ca2+ signaling and associative memory: steps through a calexcitin, ryanodine receptor, K+ channel cascade. Alkon, D. L.; Nelson, T. J.; Zhao, W.; Cavallaro, S. Trends Neurosci 1998, 21(12), 529-537.
99. Neurofilaments in health and disease. Julien, J.-P.; Mushynski, W. E. Prog Nucleic Acid Res Mol Biol 1998, 61, 1-23.
100. (a) The role of the phosphoinositide signaling system in the pathogenesis of sporadic Alzheimer's disease: a hypothesis. Fowler, C. J. Brain Res Rev. 1997, 25(3), 373-380.
101. (b) Glutamate-stimulated ROS production in neuronal cultures: interactions with lead and the cholinergic system. Savolainen, K. M.; Loikkanen, J.; Eerikainen, S.; Naarala, J. Neurotoxicology 1998, 19(4-5), 669-674.
102. Amyotrophic lateral sclerosis: the involvement of intracellular Ca2+ and protein kinase C. Krieger, C.; Lanius, R. A.; Pelech, S. L.; Shaw, C. A. Trends Pharmacol Sci. 1996, 17(3), 114-20.
103. A role for amplified protein kinase C activity in the pathogenesis of amyotrophic lateral sclerosis. Lanius, R. A.; Paddon, H. B.; Mezei, M.; Wagey, R.; Krieger, C.; Pelech, S. L.; Shaw, C. A. J Neurochem 1995, 65(2), 927-30.
104. [3H]phorbol 12,13-dibutyrate/PKC binding in thoracic spinal cord: no change in amyotrophic lateral sclerosis. Krieger, C.; Jacques, D.; Parent, A.; Quirion, R. Neuroreport 1995, 6(10), 1381-4.
105. Decrease of protein kinase C in the spinal motor neurons of amyotrophic lateral sclerosis. Nagao, M.; Kato, S.; Oda, M.; Hirai, S. Acta Neuropathol (Berl) 1998, 96(1), 52-6.
106. Pharmacology and regulation of the neuronal dopamine transporter. Reith, M. E. A.; Xu, C.; Chen, N.-H. Eur J Pharmacol. 1997, 324(1), 1-10.
107. Astrocytes and endothelins. Possibilities for tissue-repair in damaged central nervous system. Hama, H.; Uesugi, M.; Kasuya, Y.; et al. Nippon Yakurigaku Zasshi 1997, 109(3), 129-143.
108. From the bench to the bedside: the molecular management of cerebral ischemia. Maiese, K. Clin Neuropharmacol 1998, 21(1), 1-7.
109. Neurobiology of lithium: an update. Lenox, R. H.; McNamara, R. K.; Papke, R. L.; Manji, H. K. J Clin Psychiatry 1998, 59(Suppl. 6, Lithium in the Treatment of Manic-Depressive Illness: An Update), 37-47.
110. (a) T-cell signal transduction and the role of protein kinase C. Wilkinson, S. E.; Nixon, J. S. Cell Mol Life Sci 1998, 54(10), 1122-1144.
111. (b) PKC inhibitors in the therapy of autoimmune diseases. Wilkinson, S. E.; Nixon, J. S. Curr Pharm Des 1996, 2(6), 596-609.
112. Protein kinase C in IL-2 signal transduction. Lu, Y.; Durkin, J. P. Immunol Res 1997, 16(4), 355-74.
113. Intracellular mechanisms of nitric oxide plus hydrogen peroxide-mediated neutrophil adherence to cultured human endothelial cells. Okayama, N.; Coe, L.; Itoh, M.; Alexander, J. S. Inflammation Res 1998, 47(11), 428-433.
114. Okadaic acid-like toxin in systemic lupus erythematosus patients: hypothesis for toxin-induced pathology, immune dysregulation, and transactivation of herpesviruses. Mitchell, T. M. Med Hypotheses 1996, 47(3), 217-25.
115. Defective early T and T-dependent B cell activation in systemic lupus erythematosus. Fernandez-Gutierrez, B.; de Miguel, S.; Morado, C.; Hernandez-Garcia, C.; Banares, A.; Jover, J. A. Lupus 1998, 7(5), 314-22.
116. Synthesis, biological effects and pathophysiological implications of the novel arachidonic acid metabolite 5-oxo-eicosatetraenoic acid (review). Zimpfer, U.; Hofmann, C.; Dichmann, S.; Schopf, E.; Norgauer, J. Int J Mol Med 1998, 2(2), 149-153.
117. Bryostatin can induce antigen-specific nonresponsiveness in human peripheral blood T cells. Thoburn, C. J.; Hess, A. D. Transplantation Proceedings 1995, 27, 443-444.
118. Protein-Kinase C-Mediated Phosphorylation of HIV-I Nef in Human Cell-Lines. Coates, K.; Cooke, S.; Mann, D.; Harris, M. J Biol Chem 1997, 272, 12289-12294.
119. Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-κB antagonists. Mhashilkar, A. M.; Biswas, D. K.; Lavecchio, J.; Pardee, A. B.; Marasco, W. A. J Virol 1997, 71(9), 6486-6494.
120. Bryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells: Implications for use in immunocompromised patients. Stewart, J. P.; McGown, A. T.; Prendiville, J.; Pettit, G. R.; Fox, B. W.; Arrand, J. R. Cancer Chemother Pharmacol 1993, 33(1), 89-91.
121. Organic Synthesis and Biological Signal Transduction. Hinterding, K.; Alonso-Diaz, D.; Waldmann, H. Angew ChimIntEd 1998, 37, 688-749.
122. Recent developments in protein kinase C inhibitors. Harris, W.; Wilkinson, S. E.; Nixon, J. S. Expert Opin Ther Pat 1997, 7(1), 63-68.
123. The Potential for Isoenzyme-Selective Modulation of Protein-Kinase-C. Hofmann, J. Faseb J 1997, 11, 649-669.
124. Structure-activity relationships and physico-chemical properties of synthetic lipopeptide inhibitors of PKC. Hussain, R.; Sergheraert, C.; Drake, A. F.; Siligardi, G. Biomed Pept Proteins Nucleic Acids 1995, 1(2), 69-72.
125. (a) The chemistry-medicine continuum: synthetic, computer, spectroscopic and biological studies on new chemotherapeutic leads. Wender, P. A.; Martin-Cantalejo, Y.; Carpenter, A. J.; Chiu, A.; De Brabander, J.; Harran, P. G.; Jimenez, J.-M.; Koehler, M. F. T.; Lippa, B.; Morrison, J. A.; Muller, S. G.; Muller, S. N.; Park, C.-M.; Shiozaki, M.; Siedenbiedel, C.; Skalitzky, D. J.; Tanaka, M.; Irie, K. Pure Appl Chem 1998, 70(3), 539-546.
126. (b) The design, computer modeling, solution structure, and biological evaluation of synthetic analogs of bryostatin 1. Wender PA, DeBrabander, J.; Harran, P. G.; Jimenez, J. M.; Koehler, M. F.T.; Lippa, B.; Park, C. M.; Siedenbiedel, C.; Pettit, G. R. Proc Natl Acad Sci U S A 1998, 95(12), 6624-9.
127. Current Progress towards the Development of Tyrosine Kinase Inhibitors as Anticancer Agents. Bridges, A. J. Emerging Drugs 1998, 3, 279.
128. The protein kinase ABC's of signal transduction as targets for drug development. Glazer, R. I. Curr Pharm Des 1998, 4(3), 277-290.
129. Potent and selective PKC inhibitory 5-membered ring analogs of balanol with replacement of the carboxamide moiety. Jagdmann, Jr., G. E.; Defauw, J. M.; Lampe, J. W.; Darges, J. W.; and Kalter, K. Bioorg and Med Chem Lett 1996, 6(15), 1759-1764.
130. Molecular design and biological activity of potent and selective protein kinase inhibitors related to balanol. Koide, K.; Bunnage, M.;, Gomez Paloma, L.; Kanter, J. R.; Taylor, S. S.; Brunton, L. L.; Nicolaou, K. C. Chem Biol 1995, 2(9), 601-8.
131. A new class of highly selective protein kinase inhibitors: Phenylaminopyrimidines. Zimmermann, J.; Buchdunger, E.; Fabbro, D.; Geiger, T.; Mett, H.; Meyer, T.; Muller, M. et al. 215th National Meeting of the American Chemical Society April 31, 1998, Dallas, TX, 103-MEDI.
132. Recent discovery and development of selective protein kinase C inhibitors. Hu, H. Drug Discovery Today 1996, 1(10), 438-447.
133. Advances in indolo[2,3-a]carbazole chemistry: design and synthesis of protein kinase C and topoisomerase I inhibitors. Pindur, U.; Kim, Y. S.; Mehrabani, F. Curr Med Chem 1999, 6(1), 29-69.
134. Analogs of staurosporine: potential anticancer drugs? Gescher, A. Gen Pharmacol 1998, 31(5), 721-8.
135. Isozyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. Wilkinson, S. E.; Parker, P. J.; Nixon, J. S. Biochem J 1993, 294(2), 335-7.
136. Growth inhibition induced by Ro 31-8220 and calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase. Begemann, M.; Kashimawo, S. A.; Lunn, R. M.; Delohery, T.; Choi, Y.-J. A.; Kim, S.; Heitjan, D. F.; Santella, R. M.; Schiff, P. B.; Bruce, J. N.; Weinstein, B. Anticancer Res 1998, 18(5A), 3139-3152.
137. Inhibitors of protein kinase C. 3. Potent and highly selective bis(indolyl)maleimides by conformational restriction. Bit, R. A. Davis, P. D.; Elliott, L. H.; Harris, W.; Hill, C. H.; Keech, E. Kumar, H.; Lawton, G.; Maw, A.; Nixon, J. S.; Vesey, D. R. Wadsworth, J. Wilkinson, S. E. J Med Chem 1993, 36, 21-29.
138. The protein kinase C inhibitors Ro318220 and GF109203X are equally potent inhibitors of MAPKAP kinase-1β (Rsk-2) and p70 S6 kinase. Alessi, D. R. FEBS Lett 1997, 402(2,3), 121-123.
139. Inhibition of protein kinase C n by various inhibitors. Differentiation from protein kinase C isozymes. Gschwendt, M.; Dieterich, S.; Rennecke, J.; Kittstein, W.; Mueller, H.-J.; Johannes, F.-J. FEBS Lett 1996, 392(2), 77-80.
140. Selective inhibition of protein kinase C isozymes by the indolocarbazole Goe 6976. Martiny-Baron, G.; Kazanietz, M. G.; Mischak, H.; Blumberg, P. M.; Kochs, G.; Hug, H.; Marme, D.; Schachtele, C. J Biol Chem 1993, 268(13), 9194-7.
141. Partial purification of a type η protein kinase C from murine brain: separation from other protein kinase C isozymes and characterization. Zang, R.; Mueller, H.-J.; Kielbassa, K.; Marks, F.; Gschwendt, M. Biochem J 1994, 304(2), 641-7.
142. Zimmerman, J.; Buchdunger, E.; Mett, H.; Meyer, T.; Lydon, N. B.; Traxler, P. Bioorg. Med. Chem. Lett. 1996, 6, 1221-1226.
143. Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC). Zimmermann, J.; Caravatti, G.; Mett, H.; Meyer, T.; Muller, M.; Lydon, N. B.; Fabbro, D. Arch Pharm (Weinheim) 1996, 329(7), 371-6.
144. Balanol: a novel and potent inhibitor of protein kinase C from the fungus verticillium balanoides. Kulanthaivel, P.; Hallock, Y. F.; Boros, C.; et al. J Am Chem Soc 1993, 115, 6452-6453.
145. Therapeutic treatment for skin disorders using a protein kinase C inhibitor to reduce vascular permeability. Jirousek, M. R.; Stramm, L. E.; Vignati, L.; Ways, D. K. (Eli Lilly and Co., USA). PCT Int. Appl. 26 pp. WO 9848795 A1 981105.
146. Pharmaceutical compositions containing inhibitors of PKC for the treatment of central nervous system diseases associated with HIV infection. Jirousek, M. R.; Ways, D. K.; Stramm, L. E. (Eli Lilly and Company, USA). PCT Int. Appl. 31 pp. WO 9808510 A1 980305.
147. Use of protein kinase C inhibitors for the manufacture of a medicament for the treatment of AIDS. Jirousek, M. R.; Ways, D. K.; Stramm, L. E. (Eli Lilly and Company, USA). PCT Int. Appl. 37 pp. WO 9808509 A1 980305.
148. Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy. Jirousek, M. R.; Stramm, L. E.; Ways, D. K. (Eli Lilly and Company, USA; Jirousek, M. R.; Stramm, L. E.; Ways, D. K.). PCT Int. Appl. 38 pp. WO 9740842 A1 971106
149. Therapeutic treatment for sexual dysfunctions. Jirousek, M. R.; Ways, D. K.; Stramm, L. E. (Eli Lilly and Company, USA). PCT Int. Appl. 32 pp. WO 9807422 A1 980226.
150. Bis(indolylmaleimide) compounds for treatment of VEGF-related ocular diseases. Aiello, L. P.; Jirousek, M. R.; King, G. L.; Vignati, L.; Ways, D. K. PCT Int. Appl. 47 pp. WO 9740831 A1 971106.
151. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC-β inhibitor, Ishii, Hidehiro; Jirousek, M. R.; Koya, D.; Takagi, C.; Xia, P.; Clermont, A.; Bursell, S.-E.; Kern, T. S.; Ballas, L. M.; et al. Science 1996, 272(5262), 728-31.
152. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. V. Relationship between protein kinase C and ATPases. Kowluru, R. A.; Jirousek, M. R.; Stramm, L.; Farid, N.; Engerman, R. L.; Kem, T. S. Diabetes 1998, 47(3), 464-469.
153. Retinal neovascularization from experimental ischemia is inhibited by a PKC-beta inhibitor, LY333531. Danis, R. P.; Bingeman, D. P.; Jirousek, M. R.; et al. Diabetologia 1997, 40(Suppl. 1): 17.
154. Pharmacokinetics and safety of multiple oral doses of LY333531, a PKC-beta inhibitor. Demolle, D.; De Suray, J.-M.; Onkelinx, C. Clin Pharm and Therap 1999, 65, 18.
155. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Zamecnik, P. C.; Stephenson, M. L. Proc Natl Acad Sci USA 1978, 75(1), 280-4.
156. Antisense oligonucleotides as inhibitors of signal transduction: development from research tools to therapeutic agents. Dean, N. M.; McKay, R.; Miraglia, L.; Geiger, T.; Muller, M.; Fabbro, D.; Bennett, C. F. Biochem Soc Trans 1996, 24(3), 623-9.
157. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression. Dean, N.; McKay, R.; Miraglia, L.; Howard, R.; Cooper, S.; Giddings, J.; Nicklin, P.; Meister, L.; Ziel, R.; Geiger, T.; Muller, M.; Fabbro, D. Cancer Res 1996, 56(15), 3499-507.
158. Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Geiger, T.; Muller, M.; Dean, N. M.; Fabbro, D. Anticancer Drug Des 1998, 13(1), 35-45.
159. Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-alpha. Dennis, J. U.; Dean, N. M.; Bennett, C. F.; Griffith, J. W.; Lang, C. M.; Welch, D. R. Cancer Lett 1998, 128(1), 65-70.
160. Clinical development of phosphorothioate antisense oligodeoxynucleotide inhibitors of PKC-alpha mRNA (ISIS 3521, CGP 64128A) and C-rafkinase (ISIS 5132, CGP 69846A). Dorr, F. A. Arch Pharm (Weinheim) 1998, 358(Suppl. 1), 204.
161. ISIS-antisense-DNA drug claims first in halting solid tumors. Left, D. N. Bioworld Today 1997, 8, 3.
162. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression. McKay, R. A.; Miraglia, L. J.; Cummins, L. L.; Owens, S. R.; Sasmor, H.; Dean, N. M. J Biol Chem 1999, 274(3), 1715-22.
163. Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): comparison with other delivery routes. Nicklin, P. L.; Bayley, D.; Giddings, J.; Craig, S. J.; Cummins, L. L.; Hastewell, J. G.; Phillips, J. A.;Pharm Res 1998, 15(4), 583-91.
164. Phase I evaluation of CGP 64128A, an antisense inhibitor of protein kinase C-alpha, in patients with refractory cancer. Nemunaitis, J.; Eckhardt, G.; Dorr, A.; et al. 33rd Annual Meeting of the American Society of Clinical Oncology 1997, 76, 246.
165. Antisense oligonucleotide therapy targeted to protein kinase C-alpha (ISIS 3521/CGP 64128A) by 21-day infusion: results of the phase I trial and activity in ovarian carcinomas. Sikic, B. I.; Yuen, A. R.; Advani, R.; et al. 34th Annual Meeting of the American Society of Clinical Oncology 1998, 17, 429.
166. Phase I/Pharmacokinetic trial of a protein kinase C-alpha antisense oligonucleotide ISIS 3521 (CGP 64128A), administered thrice weekly. Nemunaitis, J.; Von Heff, D. D.; Homlund, J.; et al. 34th Annual Meeting of the American Society of Clinical Oncology 1998, 17, 211.
167. 0.The large-scale isolation of bryostatin 1 from Bugula neritina following current good manufacturing practices. Schaufelberger, D. E.; Koleck, M. P.; Beutler, J. A.; Vatakis, A. M.; Alvarado, A. B.; Andrews, P.; Marzo, L. V.; Muschik, G. M.; Roach, J.; et al. J Nat Prod 1991, 54(5), 1265-70.
168. Bryostatin 1 enhances lymphokine activated killer sensitivity and modulates the beta-1 integrin profile of cultured human tumor cells. Correale, P.; Caraglia, M.; Fabbrocini, A.; Guarrasi, R.; Pepe, S.; et al. Anti-Cancer Drugs 1995, 6, 285-290.
169. Bryostatins 1, 2 and 5 activate human granulocytes and lymphocytes: in vitro and in vivo studies. Eisemann, K.; Totola, A.; Jurcic, K.; Pettit, G. R.; Wagner, H. Pharm Pharmacol Lett 1995, 5(1), 45-8.
170. Bryostatin 1 (BRYO1)-induced monocytic differentiation in THP-1 human leukemia cells is associated with enhanced c-fyn tyrosine kinase and M-CSF receptors. Li, Y.; Mohammad, R. M.; Al-Katib, A.; Varterasian, M. L.; Chen, B. Leuk Res 1997, 21(5), 391-397.
171. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1. Szallasi, Z.; Du, L.; Levine, R.; Lewin, N. E.; Nguyen, P. N.; Williams, M. D.; Pettit, G. R.; Blumberg, P. M. Cancer Res 1996, 56(9), 2105-11.
172. A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Prendiville, J.; Crowther, D.; Thatcher, N.; Woll, P. J.; Fox, B. W.; et al. Brit Journ Cancer 1993, 68, 418-424.
173. A phase I trial of bryostatin 1 in patients with advanced malignancy using 24-hour intravenous infusion. Jayson, G. F.; Crowther, D.; Prendiville, J.; McGown, A. T.; Scheid, C.; et al. Brit Journ Cancer 1995, 72, 461-468.
174. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Varterasian, M. L.; Mohammad, R. M.; Eilender, D. S.; Hulburd, K.; Rodriguez, D. H.; et al J Clin Oncology 1998, 16, 56-62.
175. Phase I study of partial protein kinase C agonist bryostatin-1. Influence on the plasma concentrations of IL-6 and TNF-alpha. Philip, P. A.; Rea, D.; Balkwill, F.; et al. Brit Journ Cancer1993, 67(Suppl. 20), 17.
176. A phase II study of bryostatin 1 in metatstatic malignant melanoma. Propper, D. J.; Macaulay, V.; O'Byrne, K. J.; et al. Brit Journ Cancer 1998, 78, 1337-1341.
177. Anti-inflammatory properties of the protein kinase C inhibitor, 3-[1-[3-(dimethylamino)propyl]-1H-indol-3-yl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5- dione monohydrochloride (GF109203X) in the PMA-mouse ear edema model. Kuchera, S.; Barth, H.; Jacobson, P.; Metz, A.; Schaechtele, C.; Schrier, D. Agents & Actions 1993, 39, C170-173.
178. Differences in sensitivity to the specific protein kinase C inhibitor Ro31-8220 between small and large bronchioles of the rat. Chopra, L. C.; Twort, C. H.; Ward, J. P. Br J Pharmacol 1994, 113(4), 1237-42.
179. Growth inhibition induced by Ro 31-8220 and calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase. Begemann, M.; Kashimawo, S. A.; Lunn, R. M.; Delohery, T.; Choi, Y.-J. A.; Kim, S.; Heitjan, D. F.; Santella, R. M.; Schiff, P. B.; Bruce, J. N.; Weinstein, B. Anticancer Res 1998, 18(5A), 3139-3152.
180. Inhibition of rabbit aortic smooth muscle cell proliferation by selective inhibitors of protein kinase C. Newby, A. C.; Lim, K.; Evans, M. A.; Brindle, N. P. J.; Booth, R. F. G. Br J Pharmacol 1995, 114(8), 1652-6.
181. Palmitic acid anilide-induced respiratory burst in human polymorphonuclear leukocytes is inhibited by a protein kinase C inhibitor, Ro 31-8220. Heiskanen, K. M.; Savolainen, K. M. Free Radical Biol Med 1997, 22(7), 1175-1182.
182. RO 31-8220, a novel protein kinase C inhibitor, inhibits early and late T cell activation events. Geiselhart, L.; Conti, D. J.; Freed, B. M. Transplantation 1996, 61(11), 1637-1642.
183. Inhibitors of protein kinase C. 2. Substituted bis(indolyl)maleimides with improved potency and selectivity. Davis, P. D.; Elliott, L. H.; Harris, W.; Hill, C. H.; Hurst, S. A.; Keech, E.; Kumar, H.; Lawton, G.; Nixon, J. S.; J. Wilkinson, S. E. J Med Chem 1992, 35, 994-1001.
184. Ro 32-0432, a selective and orally active inhibitor of protein kinase C prevents T-cell activation. Birchall, A. M.; Bishop, J.; Bradshaw, D.; Cline, A.; Coffey, J.; Elliott, L. H.; Gibson, V. M.; Greenham, A.; Hallam, T. J.; Harris, W.; et al. J Pharmacol Exp Ther 1994, 268(2), 922-9.
185. th Annual Meeting of the American Assocation for Cancer Research 1997, 92.
186. Go 6976, a selective inhibitor of protein kinase C, is a potent antagonist of human immunodeficiency virus 1 induction from latent/low-level producing reservoir cells in vitro. Qatsha, K. A.; Rudolph, C.; Marme, D.; Schaechtele, C.; May, W. S. Proc Natl Acad Sci U S A 1993, 90(10), 4674-8.
187. Novel indolocarbazole protein kinase C inhibitors prevent reactivation of HIV-1 in latently infected cells. Paetzold, S.; Schneider, J.; Rudolph, C.; Marme, D.; Schaechtele, C. Antiviral Res 1993, 23(4), 273-83.
188. Imidazole and triazole substituted ether phospholipids: potent antitumor agents. Nair, H. K.; Peterson, A. C.; Yazdi, P. T.; Franzmair, R. Bioorg Med Chem Lett 1997, 7(18), 2379-2382.
189. Selective inhibition of colon cancer cell proliferation by the ether phospholipid CPR 1006. Sheffield, L. G.; Pederson, S.; Yazdi, P.; Pruss, T. Experimental biology 98, FASEB J Book of Abstracts Part II, abstract 4483, Apr1996.
190. Clarion, April 1998.